{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:36Z","timestamp":1790996616608,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00415-006-4009-z","type":"journal-article","created":{"date-parts":[[2006,8,30]],"date-time":"2006-08-30T18:07:09Z","timestamp":1156961229000},"page":"iv36-iv38","source":"Crossref","is-referenced-by-count":21,"title":["Ergoline and non-ergoline derivatives in the treatment of Parkinson\u2019s disease"],"prefix":"10.1007","volume":"253","author":[{"given":"Heinz","family":"Reichmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Bilsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Greulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg B.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"4009_CR1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","volume":"63","author":"Baseman","year":"2004","unstructured":"Baseman DG, O\u2019Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey Jr. RB (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301\u2013304","journal-title":"Neurology"},{"key":"4009_CR2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00702-005-0289-1","volume":"112","author":"Dhawan","year":"2005","unstructured":"Dhawan V,Medcalf P, Stegie F, Jackson G, Basu S, Luce P,Odin P, Chaudhuri KR (2005) Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson\u2019s disease patients treated with cabergoline. J Neural Transm 112:661\u2013668","journal-title":"J Neural Transm"},{"key":"4009_CR3","first-page":"B22","volume":"102","author":"Eggert","year":"2005","unstructured":"Eggert K, Odin P, Gasser T,Meinertz T, Strasser R, Osterspey A, Deuschl G, Oertel WH (2005) Fachgerechter Einsatz von Dopamin-Agonisten. Deutsches \u00c4rzteblatt 102:B22\u2013B23","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"4009_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","volume":"57","author":"Fitzgerald","year":"2000","unstructured":"Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JH, Abbaszade I, Hollis JM, Largent BI, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75\u201381","journal-title":"Mol Pharmacol"},{"key":"4009_CR5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/78.6.730","volume":"78","author":"Flowers","year":"2003","unstructured":"Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration\u2019s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730\u2013731","journal-title":"Mayo Clin Proc"},{"key":"4009_CR6","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","volume":"52","author":"Frucht","year":"1999","unstructured":"Frucht S, Rogers JD, Greene PE (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908\u20131910","journal-title":"Neurology"},{"key":"4009_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s007020170097","volume":"108","author":"Hanna","year":"2001","unstructured":"Hanna PA, Ratkos L, Ondo WG, Jankovic J (2001) Switching from pergolide to pramipexole in patients with Parkinson\u2019s disease. J Neural Transm 108:63\u201370","journal-title":"J Neural Transm"},{"key":"4009_CR8","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/mds.20329","volume":"19","author":"Horowski","year":"2004","unstructured":"Horowski R, Jahnichen S, Pertz HH (2004) Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 19(12):1523\u20131524","journal-title":"Mov Disord"},{"key":"4009_CR9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","volume":"19","author":"Horvath","year":"2004","unstructured":"Horvath J, Fross RD, Kleiner-Fisman G, Lerech R, Stadler H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656\u2013662","journal-title":"Mov Disord"},{"key":"4009_CR10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","volume":"513","author":"Jahnichen","year":"2005","unstructured":"Jahnichen S, Horowski R, Pertz HH (2005) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225\u2013228","journal-title":"Eur J Pharmacol"},{"key":"4009_CR11","doi-asserted-by":"crossref","unstructured":"Junghanns S, Fuhrmann JT, Simonis G, Oehlwein Ch, Koch R, Strasser RH, Reichmann H, Storch A (2006) Valvular heart disease in Parkinson\u2019s disease treated with dopamine agonists: A reader-blinded monocenter echocardiography study. Mov Disord (in press)","DOI":"10.1055\/s-2006-953000"},{"key":"4009_CR12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson","year":"2002","unstructured":"Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287:1653\u20131661","journal-title":"JAMA"},{"key":"4009_CR13","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"Parkinson","year":"2004","unstructured":"Parkinson Study Group (2004) Levodopa and the progression of Parkinson\u2019s disease. New Engl J Med 351:2498\u20132508","journal-title":"New Engl J Med"},{"key":"4009_CR14","doi-asserted-by":"crossref","unstructured":"Peralta C, Wolf E, Alber H, et al. (2006) Valvular heart disease in Parkinson\u2019s disease vs. controls: An echocardiographic study. Mov Disord; published online","DOI":"10.1002\/mds.20887"},{"key":"4009_CR15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","volume":"77","author":"Pritchett","year":"2002","unstructured":"Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280\u20131286","journal-title":"Mayo Clin Proc"},{"key":"4009_CR16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00023210-200317130-00003","volume":"17","author":"Reichmann","year":"2003","unstructured":"Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR (2003) Pramipexole in routine clinical practice: a prospective observational trial in Parkinson\u2019s disease. CNS Drugs 17:965\u2013973","journal-title":"CNS Drugs"},{"key":"4009_CR17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","volume":"10","author":"Serratrice","year":"2002","unstructured":"Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334\u2013336","journal-title":"Cardiol Rev"},{"key":"4009_CR18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","volume":"363","author":"Van Camp","year":"2004","unstructured":"Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179\u20131183","journal-title":"Lancet"},{"key":"4009_CR19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4065\/80.8.1016","volume":"80","author":"Waller","year":"2005","unstructured":"Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016\u20131020","journal-title":"Mayo Clin Proc"},{"key":"4009_CR20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"Whone","year":"2003","unstructured":"Whone AJ, Watts RL, Stoessl AJ, Brooks DJ (2003) Slower progression of Parkinson\u2019s disease with ropinirole versus levo-dopa. Ann Neurol 54:93\u2013101","journal-title":"Ann Neurol"},{"key":"4009_CR21","first-page":"P317","volume":"20","author":"Yamamoto","year":"2005","unstructured":"Yamamoto M, Uesugi T (2005) Cardiac valvulopathy in Parkinson\u2019s disease. Mov Disord 20(Suppl 10):P317","journal-title":"Mov Disord"},{"key":"4009_CR22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/S0317167100004650","volume":"33","author":"Zadikoff","year":"2006","unstructured":"Zadikoff C, Rochon P, Lang A (2006) Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 33:27\u201333","journal-title":"Can J Neurol Sci"}],"updated-by":[{"DOI":"10.1007\/s00415-008-0082-9","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2008,10,29]],"date-time":"2008-10-29T00:00:00Z","timestamp":1225238400000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-4009-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-006-4009-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-4009-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T18:28:22Z","timestamp":1736533702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-006-4009-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":22,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["4009"],"URL":"https:\/\/doi.org\/10.1007\/s00415-006-4009-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}